Details for New Drug Application (NDA): 219745
The generic ingredient in CAMCEVI ETM is leuprolide mesylate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the leuprolide mesylate profile page.
Summary for 219745
| Tradename: | CAMCEVI ETM |
| Applicant: | Accord |
| Ingredient: | leuprolide mesylate |
| Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 219745
Generic Entry Date for 219745*:
Constraining patent/regulatory exclusivity:
Dosage:
EMULSION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 219745
| Mechanism of Action | Gonadotropin Releasing Hormone Receptor Agonists |
Suppliers and Packaging for NDA: 219745
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CAMCEVI ETM | leuprolide mesylate | EMULSION;SUBCUTANEOUS | 219745 | NDA | Foresee Pharmaceuticals Co., Ltd. | 72851-100 | 72851-100-01 | 1 SYRINGE in 1 CARTON (72851-100-01) / .3 g in 1 SYRINGE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | EMULSION;SUBCUTANEOUS | Strength | EQ 21MG BASE | ||||
| Approval Date: | Aug 25, 2025 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Aug 25, 2028 | ||||||||
| Regulatory Exclusivity Use: | NEW STRENGTH | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jan 16, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jan 1, 2039 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
